The research and industrialization project of a new major infectious disease vaccine for cattle developed by Sinovet (Jiangsu) Biopharmaceuticals Co Ltd, recently received funding support.
Sinovet is a research-based high-tech enterprise for the development, manufacturing, and marketing of animal biological products. It is based in the Taizhou Medical High-tech Zone in Taizhou, Jiangsu province.
After intense rounds of competition, the project obtained a total investment of 32.5 million yuan ($4.56 million) and 8 million yuan of extra funding.
The approved project will develop a series of live vaccine products and support testing reagents for bovine infectious rhinotracheitis and bovine viral diarrhea, filling multiple domestic gaps in this field.
What's more, the project will integrate innovative key technologies for vaccine production to promote the industrial production and market promotion of products.
Sinovet mainly focuses on the research and development of new vaccines and diagnostic reagents for important infectious diseases in cattle, pigs, and pets.
At present, the company has achieved the industrialization of four types of bovine vaccines, which have been applied to domestic large-scale dairy and beef cattle-breeding enterprises.
A bird's-eye view of Sinovet (Jiangsu) Biopharmaceuticals Co Ltd. [Photo/WeChat account: weigg6666]